FDA Reports of Crohn’s Disease Treatment Side Effects Have Increased, Analysis Finds

FDA Reports of Crohn’s Disease Treatment Side Effects Have Increased, Analysis Finds
Drugs used to treat Crohn’s disease and other autoimmune disorders are among those with the greatest number of reported side effects filed with the U.S. Food and Drug Administration (FDA), according to a USA Today Network Exclusive analysis. The analysis found an increase of five times the number of side-effect reports to the FDA in 2015 from 2004 for all drugs, amounting to more than 1.2 million reports of side effects in 2015. Drugs which suppress the immune system to fight inflammation can cause serious and sometimes lethal infections including tuberculosis, and have been linked with blood disorders, including lymphoma, a blood cancer. Humira (adalimumab, manufactured by AbbVie), an FDA-approved monoclonal antibody that targets tumor necrosis factor alpha (a pro-inflammatory mediator that plays a critical role in inflammatory diseases), is one of the most widely used drugs to treat Crohn’s and other autoimmune disorders. Humira is indicated to treat children and adults with moderate to severe Crohn's disease to reduce signs and symptoms of the disease and maintain clinical remission. However, according the new analysis, the use of Humira has been linked to more than 200,000 reports of adverse events, including 4,200 deaths. But the authors of the analysis consider that the surge in side-effect reports could indicate a growing number of harmed patients or more vigilant reporting of adverse events, a goal the FDA is aiming to achieve. Experts consider that both likely play a role. Humira can also cause hepatitis B infection in carriers of the virus, allergic reactions, nervous system problems, blood problems, certain immune reactions including a lupus-like syndrome, liver problems, and new or worsening heart failure or psoriasis. Doctors shou
Subscribe or to access all post and page content.